Clinical outcomes of glaucoma treatments over a patient lifetime: A markov model

Journal of Glaucoma

Volumn 14, Issue 6, 2005, Pages 463-469

  Nordmann, Jean Philippe ^a   Lafuma, Antoine ^b   Deschaseaux, Céline ^b   Berdeaux, Gilles ^c  

^a CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^b CEMKA EVAL   (France)

^c Alcon France ^*  (France)

Author keywords

Glaucoma; Life long treatment; Modelization; Outcome research

Indexed keywords

ANTIGLAUCOMA AGENT;

ARTICLE; BLINDNESS; COHORT ANALYSIS; DEMOGRAPHY; DISEASE COURSE; GLAUCOMA; INTRAOCULAR HYPERTENSION; LIFE EXPECTANCY; LIFESPAN; LOW LEVEL LASER THERAPY; MONTE CARLO METHOD; OUTCOMES RESEARCH; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STATISTICAL MODEL; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLINDNESS; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; LASER SURGERY; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; OCULAR HYPERTENSION; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; SCOTOMA; SENSITIVITY AND SPECIFICITY; TRABECULECTOMY; VISUAL FIELDS;

EID: 27944444440     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ijg.0000184834.93535.0b     Document Type: Article

References (24)

1. Recent developments in primary open angle glaucoma and ocular hypertensions. The National Prescribing Centre MeReC Bulletin. 2003;13:17.
2. Odberg T, Jakobsen JE, Hultgren SJ, et al. The impact of glaucoma on the quality of life of patients in Norway. II. Patient response correlated to objective data. Acta Ophthalmol Scand. 2001;79:121-124.
3. Odberg T, Jakobsen JE, Hultgren SJ, et al. The impact of glaucoma on the quality of life of patients in Norway. I. Results from a self-administered questionnaire. Acta Ophthalmol Scand. 2001;79:116-120.
4. The Levobunolol Study Group. Levobunolol. A four-year study of efficacy and safety in glaucoma treatment. The Levobunolol Study Group. Ophthalmology. 1989;96:642-645.
5. Watson PG, Barnett MF, Parker V, et al. A 7 year prospective comparative study of three topical beta blockers in the management of primary open angle glaucoma. Br J Ophthalmol. 2001;85:962-968.
6. Odberg T, Sandvik L. The medium and long-term efficacy of primary argon laser trabeculoplasty in avoiding topical medication in open angle glaucoma. Acta Ophthalmol Scand. 1999;77:176-181.
7. Lotti R, Traverso CE, Murialdo U, et al. Argon laser trabeculoplasty: long-term results. Ophthalmic Surg. 1995;26:127-129.
8. Threlkeld AB, Hertzmark E, Sturm RT, et al. Comparative study of the efficacy of argon laser trabeculoplasty for exfoliation and primary open-angle glaucoma. J Glaucoma. 1996;5:311-316.
9. Nouri-Mahdavi K, Brigatti L, Weitzman M, et al. Outcomes of trabeculectomy for primary open-angle glaucoma. Ophthalmology. 1995;102:1760-1769.
10. Pojda SM, Herba E, Zatorska B, et al. [The long-term follow up after trabeculectomy]. Klin Oczna. 2001;103:161-164.
11. Edmunds B, Thompson JR, Salmon JF, et al. The National Survey of Trabeculectomy. III. Early and late complications. Eye. 2002;16:297-303.
12. Edmunds B, Thompson JR, Salmon JF, et al. The National Survey of Trabeculectomy. I. Sample and methods. Eye. 1999;13:524-530.
13. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943-1953.
14. Denis P, Lafuma A, Berdeaux G. Medical predictive factors of glaucoma treatment costs. J Glaucoma. 2004;13:283-290.
15. Denis P, Lafuma A, Berdeaux G. Medical outcome of glaucoma treatments estimated from a nationwide representative survey. Clinical Drug Investigation. 2004;24:343-352.
16. INSEE. 1990. Available at: http://www.insee.fr/. Accessed September 24, 2004.
17. Hjelmgren J, Berggren F, Andersson D. Health economics guidelines - similarities, differences and some implications. Value Health. 2001;4:225-250.
18. Brézin A, Lafuma A, Fagnani F, et al. Prevalence and burden of blindness and low vision for subjects living in institutions: a nation-wide survey. Health Qual Life Outcomes. 2005;3:27.
19. Brézin A, Lafuma A, Fagnani F, et al. Prevalence and burden of blindness, low vision and visual impairment in the community: a nation-wide survey. Arch Ophthalmol. 2005;123:1117-1124.
20. Brézin A, Lafuma A, Fagnani F, et al. Blindness, low vision and other handicaps as risk factors attached to institutional residence. Br J Ophthalmol. 2004;88:1330-1337.
21. OECD-Organisation for Economic Co-operation and Development. OECD health data: A comparative analysis of 29 Countries. Credes, 1999; Eco-Santé software, Paris.
22. Brown MM, Brown GC, Sharma S, et al. Utility values associated with blindness in an adult population. Br J Ophthalmol. 2001;85:327-331.
23. Sharma S, Brown GC, Brown MM, et al. Converting visual acuity to utilities. Can J Ophthalmol. 2000;35:267-272.
24. Hiller R, Podgor MJ, Sperduto RD, et al. High intraocular pressure and survival: the Framingham Studies. Am J Ophthalmol. 1999;128:440-445.